Cormedix Drug Patent Portfolio
Cormedix owns 1 orange book drug protected by 4 US patents Given below is the list of Cormedix's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11738120 | Synthesis of taurolidine, purity profiles and polymorphs | 15 Apr, 2042 | Active |
| US7696182 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 16 May, 2026 | Active |
| US8541393 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 02 Nov, 2024 | Expired |
| US9339036 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin | 02 Nov, 2024 | Expired |
Latest Legal Activities on Cormedix's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cormedix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Letter from FDA or Dept of Agriculture re PTE application | 19 Aug, 2025 | US7696182 |
| Maintenance Fee Reminder Mailed | 12 May, 2025 | US8541393 |
| Interim Patent Term Extension Granted | 12 May, 2025 | US7696182 |
| Email Notification | 06 May, 2025 | US7696182 |
| Change in Power of Attorney (May Include Associate POA) | 06 May, 2025 | US7696182 |
| Change in Power of Attorney (May Include Associate POA) | 30 Apr, 2025 | US7696182 |
| Requirement for information sent under 37 CFR 1.750 | 28 Feb, 2025 | US7696182 |
| Initial letter Re: PTE Application to regulating agency | 12 Aug, 2024 | US7696182 |
| Patent Term Extension Application under 35 USC 156 Filed | 08 Jan, 2024 | US7696182 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 04 Oct, 2023 | US9339036 |
|
Recordation of Patent Grant Mailed
Critical
| 29 Aug, 2023 | US11738120 |
| Mail Patent eGrant Notification | 29 Aug, 2023 | US11738120 |
| Patent eGrant Notification | 29 Aug, 2023 | US11738120 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 29 Aug, 2023 | US11738120 |
| Recordation of Patent eGrant | 29 Aug, 2023 | US11738120 |
Cormedix's Family Patents
Cormedix Drug List
Given below is the complete list of Cormedix's drugs and the patents protecting them.
1. Defencath
Defencath is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11738120 | Synthesis of taurolidine, purity profiles and polymorphs |
15 Apr, 2042
(16 years from now)
| Active |
| US7696182 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
16 May, 2026
(a month from now)
| Active |
| US8541393 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
02 Nov, 2024
(1 year, 4 months ago)
| Expired |
| US9339036 | Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin |
02 Nov, 2024
(1 year, 4 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Defencath's drug page